May 11, 2026Board meeting
Insurance Committee Meeting
The committee reviewed the status of the health plan, including market impacts from federal executive orders and legislation regarding healthcare transparency and drug pricing. Financial reports were presented comparing plan efficiency against the previous year, with a focus on high-cost claimants and the impact of PPO and HMO plan design changes. The committee discussed various cost-saving mechanisms, such as utilization management, prior authorizations, and formulary management strategies. Potential future initiatives were proposed to achieve savings, specifically the transition to biosimilars for certain specialty drugs and the implementation of a pharmaceutical importation program from tier-one countries.